Werewolf Therapeutics
$0.83
32
+$0.04+4.48% Tuesday 20:00
Statistics
Day High
0.85
Day Low
0.77
52W High
2.38
52W Low
0.53
Volume
335,210
Avg. Volume
442,745
Mkt Cap
40.41M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
7MayExpected
Expected EPS
-0.27
Actual EPS
N/A
Financials
-3,740.85%Profit Margin
Unprofitable3.77MRevenue
-141.03MNet Income
Analyst Ratings
$5.50Average Price Target
The highest estimate is 7.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow HOWL. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Merck
MRK
Mkt Cap214.76B
Gilead Sciences
GILD
Mkt Cap148.78B
AMGEN
AMGN
Mkt Cap160.66B
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Novartis
NVS
Mkt Cap237.61B
Pfizer
PFE
Mkt Cap140.15B
Roche
RHHBY
Mkt Cap258.9B
Astrazeneca
AZN
Mkt Cap256.58B
Johnson & Johnson
JNJ
Mkt Cap455.04B
About
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
Dr. Daniel J. Hicklin Ph.D.
Employees
46
Country
US
ISIN
US95075A1079
Listings
0 Comments
Share your thoughts
FAQ
What is Werewolf Therapeutics stock price today?▼
The current price of HOWL is $0.83 USD — it has increased by +4.48% in the past 24 hours. Watch Werewolf Therapeutics stock price performance more closely on the chart.
What is Werewolf Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Werewolf Therapeutics stocks are traded under the ticker HOWL.
Is Werewolf Therapeutics stock price growing?▼
HOWL stock has risen by +6.72% compared to the previous week, the month change is a +38.72% rise, over the last year Werewolf Therapeutics has showed a -4.35% decrease.
What is Werewolf Therapeutics market cap?▼
Today Werewolf Therapeutics has the market capitalization of 40.41M
When is the next Werewolf Therapeutics earnings date?▼
Werewolf Therapeutics is going to release the next earnings report on May 07, 2026.
What were Werewolf Therapeutics earnings last quarter?▼
HOWL earnings for the last quarter are -0.36 USD per share, whereas the estimation was -0.38 USD resulting in a +6.09% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Werewolf Therapeutics revenue for the last year?▼
Werewolf Therapeutics revenue for the last year amounts to 3.77M USD.
What is Werewolf Therapeutics net income for the last year?▼
HOWL net income for the last year is -141.03M USD.
How many employees does Werewolf Therapeutics have?▼
As of April 01, 2026, the company has 46 employees.
In which sector is Werewolf Therapeutics located?▼
Werewolf Therapeutics operates in the Health Care sector.
When did Werewolf Therapeutics complete a stock split?▼
Werewolf Therapeutics has not had any recent stock splits.
Where is Werewolf Therapeutics headquartered?▼
Werewolf Therapeutics is headquartered in Watertown, US.